Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 57 of 88 · 4195 articles
The study provides real-world effectiveness and safety data for risankizumab in a largely difficult-to-treat Crohn's population, showing about half achieved corticosteroid-free clinical remission at 24 weeks —...
This helps people with IBD and their care teams make delivery plans: if perianal disease is not active, having IBD alone was not linked to higher perineal injury risk in first-time vaginal births in this study.
The oral microbiome in children with Crohn's disease appears to reflect disease severity and changes with treatment, suggesting a potential noninvasive biomarker for monitoring response to nutritional therapies like CDED...
IBD and other lower-GI disorders may benefit from oral hydrogel platforms that improve local drug delivery while deliberately engaging the gut microbiota. Understanding this research direction helps patients and...
Adding partial enteral nutrition to ustekinumab was associated with better clinical, endoscopic, radiologic, and nutritional outcomes at 52 weeks in this multicentre real-world cohort of Crohn’s disease patients. This...
The study describes a colon-targeted delivery system that enhanced local anti-inflammatory, barrier-repair, and microbiota-restoring effects of celastrol in a mouse UC model. If translatable, this approach could lead to...
People with IBD or other autoimmune diseases are often concerned that vaccines might work less well for them.
Researchers identified a strain-variable adhesin (Hil1) in the food-associated yeast Debaryomyces hansenii that affects adhesion and is recognized by antibodies from Crohn disease patients.
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Phytomedicine.
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Drug...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from International Journal...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Microbiome. The original article is from Materials Today Bio.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Microbiological Research.
People with IBD may see growing interest in nonpharmacologic approaches like acupuncture; this review summarizes preclinical evidence suggesting acupuncture can reduce inflammation and support intestinal barrier proteins...
This study suggests that genetic risk for Crohn disease and ulcerative colitis may causally increase the risk of developing ankylosing spondylitis, an inflammatory joint condition that commonly co-occurs with IBD.
If true, a causal link between IBD and pancreatitis could help explain why people with Crohn’s disease or ulcerative colitis sometimes develop acute or chronic pancreatitis and could guide research into shared biological...
Patients with IBD receiving biologic therapy need regular lab monitoring, TB screening, vaccinations, and bone-density assessment; many of these services were underused before the dashboard. Tools that improve those...
This study suggests that people with PSC-IBD may respond differently to some biologic treatments: infliximab and vedolizumab had similar early effectiveness versus IBD alone, but ustekinumab showed a lower early response...
This study suggests adults with moderate-to-severe atopic dermatitis may have a higher-than-expected prevalence of IBD compared with general population estimates, and AD often precedes IBD—so dermatologists and patients...
People with IBD and their clinicians are often looking for objective ways to monitor disease-related changes. This study suggests morning HRV may add useful, noninvasive information about condition and readiness in an...
This preclinical study suggests cigarette smoke alters gut microbes and metabolites in ways that can either protect or worsen colitis depending on the model; it identifies 4-HBA as a metabolite that reduced inflammation...
This large pediatric registry study suggests children starting infliximab biosimilars have similar 12‑month clinical outcomes and treatment durability as those starting the originator drug — reassuring for patients and...
Frailty is linked to worse outcomes in older people with IBD, so knowing how common it is—and which patients are at higher risk—can influence monitoring and treatment planning.
Adolescents and young adults with IBD commonly face pain and may receive opioids; a digital tool designed with patient and clinician input could help reduce opioid-related risks and improve coordination of pain care.
Shows which IBD comorbidities may be driven in part by shared inherited genetic risk and which likely reflect non-genetic factors, information that could shape future risk stratification and screening approaches for...
This study links bile-acid signaling through FXR in dendritic cells to regulation of Tph cells, a T-cell subset found in IBD. Understanding these immune pathways could point to new biological mechanisms relevant to...
Granulomas on biopsy can indicate infection, IBD (including Crohn’s), sarcoidosis, or malignancy; knowing the likely causes and gaps in diagnostic testing helps guide follow-up. The diagnosis mix differed by organ and...
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
Market shifts — including more biosimilars, expanding biologic and small-molecule options, and wider online pharmacy access — can affect how quickly and affordably new Crohn’s treatments reach patients. Patients on...
The study suggests a common food (edible bird's nest) may influence gut inflammation, barrier function, and microbiota in ways that could be relevant to IBD research and future dietary interventions.
Automating bowel wall thickness measurement could make intestinal ultrasound more consistent and reliable for monitoring inflammation in IBD, which matters to patients and clinicians tracking disease activity.
Patients with IBD who are frail appear to have a substantially higher risk of infections while on biologic therapies compared with fit patients. Recognizing frailty before and during treatment could improve risk...
People with IBD commonly have extraintestinal symptoms (mood disorders, fatigue, pain, nutritional problems) that affect quality of life and need proactive identification and management in primary care.
The study explores engineering HSPCs to induce IL-10–mediated, antigen-specific regulatory responses, which could lead to new cell-based strategies for children with refractory IBD who do not respond to current...
People with IBD sometimes are excluded from or uncertain about immune checkpoint inhibitor cancer trials because of concerns about triggering autoimmune flares. This trial explicitly studies safety and disease impact in...
A Phase 3 trial is testing whether guselkumab can produce MRI-detected transmural healing in Crohn's disease — an outcome that could reflect deeper intestinal healing than symptom improvement alone. If successful, it may...
The Crohn's & Colitis Foundation is a major patient advocacy organization for people with IBD; changes in its staffing or hiring could affect programs, support services, or community outreach over time.
A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...
Based on the title and source metadata, this appears to be an observational study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from cureus.com.
People with IBD who are breastfeeding and are taking guselkumab may want data on how much of the drug gets into breast milk and the estimated infant exposure. This study aims to provide those measurements for the Q4W and...
This Phase 3 trial directly compares two IL-23–targeting biologic therapies in moderate-to-severe Crohn's disease with a 52-week deep remission endpoint, which could inform future treatment choices if results are...
This registered Phase 2 trial tests guselkumab, golimumab, and a new investigational agent (JNJ-78934804) in adults with moderate–severe ulcerative colitis who previously failed advanced therapies. Results could affect...
Long-term safety data on biologics and thiopurines are important for people with ulcerative colitis because they help patients and clinicians weigh risks (including malignancies and pregnancy-related outcomes) when...
This registry will collect one-year, patient-reported outcomes on symptom control and clinical remission while people with IBD receive Zymfentra (infliximab-dyyb) in routine care — information that may help patients and...
A new IL-23–targeting therapy (JNJ-78934804) is being tested against an approved IL-23 inhibitor (guselkumab) in a large Phase 3 trial for moderate–severe ulcerative colitis, which could affect future treatment options...
This trial tests whether pomegranate juice can lower fecal calprotectin, a commonly used marker of intestinal inflammation, in people with IBD in remission. If effective, such a dietary approach could be of interest to...
A new Phase 3 trial is testing icotrokinra, an oral investigational drug, for induction and maintenance of remission in moderate–severe ulcerative colitis. Trials like this could expand treatment options if the drug...
Accepted applications for a vedolizumab biosimilar could lead to another treatment option for adults with moderate‑to‑severe ulcerative colitis and Crohn’s disease and may improve access or affordability if approved.
